NCT04871646

Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of CKD-314

A Double-blind, Multi-center, Multi-regional, Randomized Controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed With COVID-19

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 586 (estimated)
• Sponsor: Chong Kun Dang Pharmaceutical · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A Double-blind, Multi-center, Multi-regional, Randomized controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed with COVID-19

Detailed description

To evaluate the efficacy and safety of CKD-314 by comparing the study group and control group in hospitalized adult patients diagnosed with COVID-19 pneumonia

Conditions

• COVID-19 Pneumonia

Interventions

Type	Name	Description
DRUG	CKD-314+SOC	CKD-314 is administered intravenously and standard of care is also performed.
DRUG	CKD-314 Placebo+SOC	CKD-314 placebo is administered intravenously and standard of care is also performed..

Timeline

• Start date: 2021-06-30
• Primary completion: 2022-03-01
• Completion: 2022-08-01
• First posted: 2021-05-04
• Last updated: 2021-08-02

Locations

1 site across 1 country: South Korea